Reading the Mounjaro Information Leaflet: What People Get Wrong

The misconception: the leaflet is boilerplate you can skip

It is probably the most common thing people say after their first pen arrives, the leaflet looks intimidating, runs to several folded pages of small text, and feels like the legal disclaimer at the end of a car advert. So it gets folded back up and left in the box. This is the biggest practical mistake a new Mounjaro patient can make.

The patient information leaflet for Mounjaro (tirzepatide) is a regulatory document produced under MHRA oversight and based directly on the medicine's Summary of Product Characteristics. That means every instruction in it, from the injection technique steps to the storage temperature range, is there because clinical evidence or regulatory review put it there. When our prescribers field questions about missed doses, injection-site reactions, or what to do before a procedure, the answer is always grounded in the same document. Reading it once, properly, tends to head off the most common worries before they become phone calls.

The full text of the Mounjaro patient information leaflet is also available on the Electronic Medicines Compendium (eMC), which publishes the authorised UK version and notes when it was last updated, useful if you want to check you have the current edition.

What the leaflet actually contains about doses and timing

The licensed UK dose range for Mounjaro runs from 2.5 mg up to 15 mg, and the leaflet describes the full schedule. The 2.5 mg starting dose exists to give your system time to adjust, not to produce the therapeutic effect you are aiming for, the prescriber titrates from there, typically in four-week steps, according to how you are tolerating each level.

On timing: Mounjaro is a once-weekly injection, taken on the same day each week where possible. The leaflet is specific about what to do if you miss a dose, the window and the guidance depend on how close the next scheduled dose is, and the leaflet states this plainly. The right day to take your weekly dose is one of the things worth planning around your routine. Some people find anchoring it to the start of the working week, or to a specific evening, makes it easier not to miss. If you are ordering on a regular cycle, ordering before a bank holiday or a planned trip means your supply does not arrive late.

For detailed information about how tirzepatide works at a pharmacological level, the NHS medicines page for tirzepatide is the most accessible Tier-1 reference.

Side effects: reading the frequency categories correctly

The side effects section is where the leaflet is most frequently misread. When it says a side effect is "very common" (affecting more than 1 in 10 people), that does not mean severe or dangerous, it means frequent, usually mild, and in clinical trials most noticeable in the first few weeks after starting or after a dose increase. The gastrointestinal effects reported most often are nausea, diarrhoea, reduced appetite, vomiting, and constipation. For most people these settle as the body adjusts.

The leaflet also describes effects that are less common but need prompt attention. Severe, persistent stomach pain that spreads to the back, with or without vomiting, should be assessed urgently, the MHRA's Drug Safety Update from January 2026 specifically highlighted acute pancreatitis as an infrequent but serious known risk with GLP-1 medicines. Gallbladder problems, signs of an allergic reaction, and significant dehydration from ongoing GI symptoms are also listed as reasons to seek medical help quickly. The leaflet tells you which symptoms to take seriously and which to monitor; reading that section once is worth more than any summary.

You can report a suspected side effect directly through the MHRA Yellow Card scheme, which is also referenced in the leaflet itself. For a broader overview of the Mounjaro information that is relevant to starting treatment, our education pages set out the clinical context clearly.

Storage, the KwikPen, and what the leaflet says about injection technique

Each Mounjaro KwikPen contains four weekly doses (one per weekly injection), and the leaflet walks through the injection process step by step: checking the pen, selecting an injection site (abdomen, thigh, or upper arm, rotated each week), and how to confirm the dose has been delivered. These steps matter practically. Injecting into the same spot repeatedly can cause skin changes that affect absorption, and the leaflet explains site rotation for exactly that reason.

Storage is covered with the same specificity. Mounjaro should be refrigerated at 2–8°C. There is a limited window during which a pen can be kept at room temperature, and the leaflet states the exact duration and the maximum temperature, always defer to your leaflet for the precise figures, since they are the authorised reference and could change if the SmPC is updated.

If you are considering starting Mounjaro as part of a weight loss programme, or want to understand the clinical criteria a prescriber applies, our treatment overview explains how the consultation works. For questions specific to using the pen, the Mounjaro leaflet guidance on our site walks through the practical steps in plain language. A downloadable PDF version is also available if you prefer to keep a copy to hand.

On cost: if you are thinking about the financial side of private treatment, the context behind what Mounjaro costs privately in the UK is covered separately, including what an honest price should include. Speak to our prescribers if you have clinical questions about whether Mounjaro is right for you, the consultation is free, and a named clinician reviews every application personally.